Regeneron Crushes Q2 Estimates, Raises Margin Outlook on Dupixent and Eylea HD Strength
REGN sits 33% above its 52-week low of $541.
Summary
Regeneron delivered a massive Q2 beat with revenue of $4.29B, 12% above consensus, and adjusted EPS of $14.29, nearly 40% above estimates. The beat was driven by Dupixent collaboration revenue (global sales up 38%) and record Eylea HD U.S. sales (up 52%). Management raised 2026 gross margin guidance and lowered capex, signaling improved profitability. The full repayment of the Sanofi Development Balance means collaboration profits will increase starting Q3. This follows Sanofi's own strong Dupixent-driven results earlier today, confirming the franchise's momentum. The stock, trading at a compressed 14x forward earnings, now has a clear catalyst for multiple expansion.
At the time of this announcement, REGN was trading at $717.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $72.9B. The 52-week trading range was $541.00 to $821.11. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.